common side effects of crixivan
nephrolithiasis
urolithiasis
comprehensive list of adverse effects
renal side effects
nephrolithiasis/urolithiasis
flank pain
hematuria
ranging
individual studies
patients
receiving indinavir
active ingredient
crixivan
usual dose during clinical trials
developed hydronephrosis
stent placements
increased creatinine
times uln
patients
receiving indinavir
zidovudine
lamivudine
capillary necrosis
pyuria
nephrolithiasis/urolithiasis
resulting in renal insufficiency
acute renal failure
interstitial nephritis
indinavir crystal deposits
pyelonephritis
bacteremia
renal insufficiency
renal failure
postmarketing experience
incidence of nephrolithiasis/urolithiasis
doses
g/day
according
manufacturer
indinavir
component of the kidney stones
patients
additional risk
concomitant use of crystalluria-inducing medications
sulfonamides
postmarketing experience
interstitial nephritis
patients
stopping indinavir
hepatic side effects
asymptomatic hyperbilirubinemia
total bilirubin
mg/dl
patients
frequency
doses
g/day
patients
concomitant elevations in alt
ast
elevated alt
times uln
ast
times uln
total serum bilirubin
times uln
serum amylase
times uln
hepatitis
hepatic failure
hepatic cytolysis
pancreatitis
including at least
case with lactic acidosis
jaundice
liver function abnormalities
serum triglycerides
cirrhosis
postmarketing experience
gastrointestinal side effects
nausea
diarrhea
vomiting
acid regurgitation
anorexia
appetite
dyspepsia
jaundice
dry mouth/lips
nausea
vomiting
zidovudine
other nucleoside analog
reverse transcriptase inhibitors
abdominal distention
dyspepsia
postmarketing experience
dermatologic side effects
rash
pruritus
dry skin
leukocytoclastic vasculitis
rash
including
stevens-johnson syndrome
erythema multiforme
nail
skin hyperpigmentation
ingrown toenails
paronychia
pruritus
alopecia
postmarketing experience
genitourinary side effects
nephrolithiasis/urolithiasis
including
renal colic
flank pain
hematuria
dysuria
hematuria
nocturia
proteinuria
urinary frequency
urinary tract infection
indinavir-induced neuropathy
erectile dysfunction
leukocyturia
crystalluria
dysuria
postmarketing experience
cases of acute spontaneous bleeding in hemophiliacs
protease inhibitors in general
hematologic side effects
decreased hemoglobin
anemia
platelets
neutrophils
platelets
lymphadenopathy
spleen disorder
hemolytic anemia
increased spontaneous bleeding in hemophiliacs
acute hemolytic anemia
postmarketing experience
postmarketing report
average time
onset of protease inhibitor
pi
related hyperglycemic event
days
cases
days after the initiation of therapy
disorder
cases
hospitalizations
incidents of diabetic ketoacidosis
underlying mechanism for the development of pi-related hyperglycemia
pis
peptidomimetic inhibitors
conversion of proinsulin
insulin via the calcium-dependent endopeptidases
peripheral insulin resistance
impaired glucose tolerance
pi-treated subjects
study
patients
receiving pi therapy
blood glucose levels
metabolic side effects
increased blood glucose
insulin resistance
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
patients
receiving protease inhibitors
including indinavir
causal relationship
new-onset diabetes mellitus
hyperglycemia
exacerbation
existing diabetes
serum cholesterol
postmarketing experience
indinavir deposition in synovial fluid
monoarthritis in a patient
intraarticular indinavir
active ingredient
crixivan
levels of mcg/ml
patient
knee joint
musculoskeletal side effects
pain
acute monoarthritis
enthesopathies
adhesive capsulitis
myalgia
muscle cramps
muscle weakness
stiffness
muscle pain
arthralgia
postmarketing experience
nervous system
side effects
headache
dizziness
somnolence
agitation
bruxism
dream abnormality
dysesthesia
fasciculation
hypesthesia
neuralgia
peripheral neuropathy
tremor
vertigo
epidural lipomatosis
sensory loss
syncope
peripheral paresthesia
oral paresthesia
postmarketing experience
respiratory side effects
cough
dyspnea
halitosis
pharyngitis
rales/rhonchi
respiratory distress
upper respiratory infections
immunologic side effects
immune reconstitution syndrome
autoimmune disorders
graves
disease
polymyositis
guillain-barre syndrome
setting of immune reconstitution
cardiovascular
side effects
myocardial infarction
angina pectoris
hypertension
cerebrovascular disorder
postmarketing experience
hypersensitivity side effects
anaphylactoid reactions
urticaria
vasculitis
postmarketing experience
psychiatric side effects
anxiety
neurosis
depression
postmarketing experience
other side effects
abdominal pain
taste perversion
asthenia/fatigue
fever
malaise
angiolipomatosis
postmarketing experience
ocular side effects
blurred vision
eye pain
eye
orbital edema
endocrine side effects
galactorrhea
hyperprolactinemia
blood in the urine
sharp back pain
ribs
stomach pain
chills
clay-colored stools
dark urine
dizziness
fever
headache
itching
loss of appetite
nausea
rash 
unpleasant breath odor
unusual tiredness
weakness
vomiting of blood
yellow eyes
skin
confusion
dehydration
itchy skin
fruity mouth odor
increased hunger
increased thirst
increased urination
pale skin
troubled breathing with exertion
unusual bleeding
bruising
unusual tiredness
weakness
vomiting
weight loss
change in sense of taste
diarrhea
difficulty with sleeping
generalized weakness
acid
sour stomach
acid regurgitation
belching
cough
general feeling of discomfort
illness
heartburn
increase in appetite
indigestion
sleepiness